Effects of partial deletions within the human immunodeficiency virus type 1 V3 loop on coreceptor tropism and sensitivity to entry inhibitors
anti-retroviral drugs, such as Pfizer's Selzentry therapy, which is the first in its class to be FDA approved, block the CCR5 co-receptor to inhibit disease progression.
We are also very grateful to NIAID scientists for including Samaritan's SP-10 in this study; and look forward to the further development of SP-10, as an oral entry inhibitor
, for HIV and HCV.
gain attention as a potential new class of antiretrovirals.
HIV entry inhibitors
in early development DRUG NAME CURRENTLY GIVEN COMPANY AMD-070 By mouth Anormed AMD-887 By mouth Anormed PRO-140 By injection or infusion * Progenics BMS-488043 By mouth Bristol-Myers Squibb UK 427,857 By mouth Pfizer SP-01A By mouth Samaritan Pharmaceuticals SCH-D By mouth Schering Plough TNX-355 By infusion Tanox GSK(GW)-873140 By mouth GlaxoSmithKline PRO-542 By injection or infusion * Progenics * infusion is when medication is given directly into a vein over a period of time.
Currently, there are 4 groups of antiretroviral medications used to treat HIV/AIDS: 1) nucleoside/nucleotide reverse transcriptase inhibitors or "nukes," 2) non-nucleoside reverse transcriptase inhibitors or "non-nukes," 3) protease inhibitors, and 4) entry inhibitors
(see table below).
The entry inhibitor
nearest to market is T-20 (enfuvirtide).
Viral entry inhibitors
represent a novel and interesting new class of antiviral agents," said John McHutchison, MD, Professor of Medicine at Duke University and Chairman of iTherX Scientific and Clinical Advisory Board.
In the area of virology, Progenics is developing the HIV entry inhibitor
PRO 140, a humanized monoclonal antibody targeting the entry co-receptor CCR5, which is in phase 2 clinical testing.
The mechanism of T-20 is well established in clinical trials and this agent is likely to be the first entry inhibitor
to gain US Food & Drug Administration (FDA) approval.
An oral entry inhibitor
taken as an adjunct, SP-01A is easy for patients to take in pill form and can improve quality of life by enabling users to decrease the dosage of currently taken anti-retroviral drugs, thereby reducing side effects.
Continue planning, through our collaboration with Pfizer, for possible use of our Co-Receptor Tropism Assay with Pfizer's maraviroc and other CCR5 entry inhibitor
drugs in potential early access programs as well as in commercial use around the world following approval of the drugs by the FDA and international regulatory agencies.
Tanox's Novel HIV Entry Inhibitor
Exhibits Synergy with Enfuvirtide to Inhibit HIV
whether it uses the CCR5 or CXCR4 co-receptor, or both), * screen for new entry inhibitor
compounds, and * test for antibody responses capable of blocking infection, a critical need in assessing HIV vaccines.
In 2005-2006, the guidelines established maximal suppression of HIV as the goal of therapy in this patient population, and recommended the use of an entry inhibitor
(such as FUZEON) with an active ritonavir-boosted protease inhibitor (such as darunavir) as a strategy for achieving that goal.